Literature DB >> 12443882

Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid.

Takeo Hirano1, Masahiro Kizaki, Kuniki Kato, Fuminori Abe, Natsuko Masuda, Kazuo Umezawa.   

Abstract

All-trans retinoic acid (ATRA) induces the differentiation of acute promyelocytic leukemia (APL) cells into neutrophils. We found that bestatin, an inhibitor of CD13/aminopeptidase N, enhanced the sensitivity of APL NB4 cells to ATRA at concentrations of 0.1-1000ng/ml. A structurally different aminopeptidase N inhibitor, actinonin, also increased the effect of ATRA on differentiation, but an inactive stereoisomer of bestatin, (2R,3S)-AHPA-(R)-Leu, did not. Bestatin synergistically enhanced the cytostatic effect of ATRA on NB4 cells. Masking of the cell-surface CD13 by anti-CD13 antibody WM15 blocked the synergistic effect of bestatin and ATRA on differentiation. Thus bestatin, an immunomodulator clinically used for nonlymphocytic leukemia, synergistically increased the ATRA-induced differentiation of NB4 cells by inhibiting CD13/aminopeptidase N on the cell-surface.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12443882     DOI: 10.1016/s0145-2126(02)00052-8

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Marked reduction of LL-37/hCAP-18, an antimicrobial peptide, in patients with acute myeloid leukemia.

Authors:  Li-Li An; Xiao-Tong Ma; Ying-Hua Yang; Yong-Min Lin; Yu-Hua Song; Ke-Fu Wu
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

2.  A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Wasim K Bleibel; Emily O Kistner; Wei Zhang; Tyson A Clark; Tina X Chen; Anthony C Schweitzer; John E Blume; Nancy J Cox; M Eileen Dolan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-30       Impact factor: 11.205

Review 3.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

4.  Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer.

Authors:  Hirohisa Tsukamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Akihiro Nawa; Fumitaka Kikkawa
Journal:  BMC Cancer       Date:  2008-03-19       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.